Newly debuted biotech shoots for $40M IPO; Intellia touts new animal data on CRISPR/Cas9
⇨ Just 8 months after making its debut at the beginning of the year, Cambridge, MA-based Cue Biopharma has filed for a $40 million IPO. The TCR company is based on work done at Albert Einstein College of Medicine. The biotech window has opened considerably in the last few months, but a fledgling company like this could well test investors’ appetite for the unknown. According to the S-1, they’re still involved in preclinical work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.